Ignite Creation Date:
2025-12-24 @ 3:35 PM
Ignite Modification Date:
2026-01-11 @ 1:08 AM
Study NCT ID:
NCT05320692
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-12-11
First Post:
2022-04-02
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular Carcinoma
Sponsor:
Jiangsu HengRui Medicine Co., Ltd.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-08-09
Start Date Type:
ACTUAL
Primary Completion Date:
2026-07-30
Primary Completion Date Type:
ESTIMATED
Completion Date:
2026-07-30
Completion Date Type:
ESTIMATED
First Submit Date:
2022-04-02
First Submit QC Date:
None
Study First Post Date:
2022-04-11
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-12-10
Last Update Post Date:
2025-12-11
Last Update Post Date Type:
ESTIMATED